Wątek et al. confirmed that gelsolin concentrations in blood and bone marrow samples from AML patients are significantly lower when compared to its concentration in plasma of healthy controls, which results from disturbed gelsolin-actin interaction, binding of gelsolin to cellular mediators, or modulation of gelsolin synthesis in response to actin release. Here, GSN is linked to acute myeloid leukemia.